VYNE Therapeutics (VYNE) FCF Margin (2017 - 2026)
VYNE Therapeutics (VYNE) posted FCF Margin of 4745.35% for Q1 2026, up 56.22% on a QoQ basis from 10839.0% in Q2 2025, and up 98515.0% year-over-year from N/an in Q1 2025.
VYNE Therapeutics (VYNE) FCF Margin (2017 - 2026) Analysis & Trends
VYNE Therapeutics' FCF Margin history runs 10 years deep, the most recent figure standing at 4745.35% for Q1 2026.
- Quarterly FCF Margin rose 98515.0% year-over-year to 4745.35% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5624.95% (up 59632.0% YoY) and the FY2025 annual result came in at 5811.23%, up 100657.0% from the prior year.
- FCF Margin was 4745.35% for Q1 2026 at VYNE Therapeutics, up from 10839.0% in the prior quarter.
- Across five years, FCF Margin topped out at 4266.47% in Q3 2022 and bottomed at 16589.66% in Q4 2022.
- A 5-year average of 7349.83% and a median of 6527.78% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin tumbled 1278233 bps — and 2023, when it soared 983044 bps.
- VYNE Therapeutics' FCF Margin stood at 16589.66% in 2022, then soared by 59 bps to 6759.21% in 2023, then sank by 60 bps to 10842.17% in 2024, then climbed by 0 bps to 10839.0% in 2025, then soared by 56 bps to 4745.35% in 2026.
- Business Quant data shows VYNE's FCF Margin at 4745.35% in Q1 2026, 10839.0% in Q2 2025, and 5730.5% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | -4,745.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,745.35% |
| Jun 30, 2025 | -10,839.00% |
| Mar 31, 2025 | -5,730.50% |
| Dec 31, 2024 | -10,842.17% |
| Sep 30, 2024 | -7,033.06% |
| Jun 30, 2024 | -4,283.84% |
| Mar 31, 2024 | -7,981.00% |
| Dec 31, 2023 | -6,759.21% |
| Sep 30, 2023 | -4,519.30% |
| Jun 30, 2023 | -9,574.00% |
| Mar 31, 2023 | -5,478.00% |
| Dec 31, 2022 | -16,589.66% |
| Sep 30, 2022 | -4,266.47% |
| Jun 30, 2022 | -6,527.78% |
| Mar 31, 2022 | -5,078.09% |
| Dec 31, 2021 | -3,807.33% |
| Sep 30, 2021 | -12,932.33% |
| Jun 30, 2021 | -5,350.85% |
| Mar 31, 2021 | -5,281.30% |
| Dec 31, 2020 | -592.04% |